Original Research ARTICLE
CD4+CD25+LAG3+ T Cells With a Feature of Th17 Cells Associated With Systemic Lupus Erythematosus Disease Activity
- 1Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
- 2Department of Immunotherapy Management, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
- 3Max Planck-The University of Tokyo Center for Integrative Inflammology, The University of Tokyo, Tokyo, Japan
- 4Center for Integrative Medical Sciences, The Institute of Physical and Chemical Research, Yokohama, Japan
Systemic lupus erythematosus (SLE) is an autoimmune disease that involves multiple immune cell subsets. We analyzed immune cell subsets in human peripheral blood mononuclear cells (PBMC) in order to identify the cells that are significantly associated with SLE disease activity and treatment. The frequencies of various subsets of CD4+ T cells, B cells, monocytes and NK cells in PBMC were assessed in 30 healthy controls (HC), 30 rheumatoid arthritis (RA) patients and 26 SLE patients using flow cytometry. The correlations between subset frequencies in SLE and clinical traits including Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) were examined. Changes in subset frequencies after the treatment in SLE patients were investigated. We focused on CD25+LAG3+ T cells and investigated their characteristics, including cytokine secretion, mRNA expression and suppression capacity. We assessed correlations between CD25+LAG3+ T cells and SLEDAI by Spearman's rank correlation coefficient. CD25+LAG3+ T cells were significantly increased in SLE whereas there were few in RA and HC groups. CD25+LAG3+ T cell frequencies were significantly correlated with SLEDAI and were increased in patients with a high SLEDAI score (> 10). CD25+LAG3+ T cells produced both IL-17 and FOXP3, expressed mRNA of both FOXP3 and RORC and lacked suppressive capacity. CD25+LAG3+ T cells were associated with disease activity of SLE. CD25+LAG3+ T cells had features of both CD25+FOXP3+ regulatory T cells (CD25+ Treg) and Th17. CD25+LAG3+ T cells could be associated with the inflammatory pathophysiology of SLE.
Systemic lupus erythematosus (SLE) is an autoimmune disease that is characterized by loss of tolerance, production of autoantibodies, immune complex deposition, and end organ damage. Multiple immune cell subsets are involved in the pathophysiology of SLE. SLE appears to be induced by persistent apoptotic debris (1) that primes neutrophils' NETosis (2), induces plasmacytoid dendritic cells to produce type I interferons that reduce B cell tolerance (3) and decreases regulatory T cell (Treg) function (4).
There are many reports demonstrating changes in the frequencies of immune cell subsets in peripheral blood mononuclear cells (PBMCs) of SLE patients. Whereas, naïve CD4+ T cells (5) decreased in frequency in SLE, activated effector memory T cells (6), Th1 (7), Th17 (8), and follicular helper T cells (Tfh) (9) all increased. Naïve B cells decreased, and plasmablasts and plasma cells increased in SLE (10, 11). On the other hand, in SLE patients, the reported changes in the frequencies of CD4+CD25+ regulatory T cells (CD25 Tregs) that express FOXP3 (12, 13) are still controversial (14–16).
At present, it is not clear which PBMC subsets are significantly correlated with SLE disease activity. SLE pathology is reportedly associated with Th17 (8), FOXP3+Helios+ Treg (17, 18), and plasma cells (19). Based on available studies, we concluded that comprehensive analysis of immune cell subsets was necessary to directly compare the association between disease activity and individual immune cell subsets. The present analysis of human PBMC was standardized by using the gating and staining strategies recommended by the Human Immunological Project Consortium (HIPC) (20).
Here, we observed a correlation between the frequencies of specific cell subsets and clinical traits in SLE, and the effect of treatment on the frequencies of those cell subsets. We included an expression analysis of lymphocyte activation gene 3 (LAG3) in a CD4+ regulatory T cell analysis panel. LAG3 is a member of the immunoglobulin superfamily that strongly binds to MHC class II (21). LAG3-expressing cells were identified as IL-10-producing regulatory T cells (Tr1) in human PBMC (22), and CD4+LAG3+ T cells were usually negative for both CD25 and FOXP3 expression. Human CD4+CD25−LAG3+ T cells (CD25−LAG3+ T cell) were detected in both PBMC (23, 24) and tonsils (25) that produced high amounts of IL-10, expressed low levels of FOXP3, and suppressed antibody production of B cells.
Materials and Methods
Human Samples and Clinical Data
We recruited 26 SLE patients, 30 rheumatoid arthritis (RA) patients and 30 self-reported screened healthy controls (HC). Individuals under 20 years of age or with active infection were excluded. SLE patients fulfilled the 1982 American College of Rheumatology criteria for SLE or the 2012 SLICC Classification criteria for SLE. RA patients fulfilled the 1987 revised criteria of the American College of Rheumatology or the 2010 ACR/EULAR classification criteria. The following clinical data were collected for both SLE and RA patients: disease duration, white blood cell count (WBC) (normal range is 3,300–8,600 cells/μL), and total lymphocyte count calculated by multiplying the WBC concentration by the percentage of lymphocytes in a complete blood cell count. The following clinical data were collected only in SLE: SLE disease activity index (SLEDAI) (26), total complement activity (CH50) (normal range is 31.8–48.7 U/mL), and anti-double stranded DNA (dsDNA) antibody titer measured by fluorescence-enzyme immunoassay (cut off value is 10 IU/mL). All clinical investigations conformed to the Declaration of Helsinki principles and were approved by the ethics committee of the University of Tokyo (No. 10154 and G3582). Peripheral blood and clinical data were collected after getting written informed consent in accordance with our ethical review board. Peripheral blood was collected once from each donor, except for four SLE patients whose samples were taken multiple times during the course of treatment. In the case of one SLE sample, the frequencies of cell subsets (except for activated CD25+ Treg, CD25+ Treg, CD25−LAG3+ T cell, and CD25+LAG3+ T cells) were excluded because of a change of gating strategy.
Flow Cytometric Analysis
PBMCs were isolated from whole blood by Ficoll-Paque Plus (GE Healthcare) gradient separation. Fc Receptor Binding Inhibitor (eBioscience) was added to the isolated PBMCs. They were stained with the fluorescent-labeled antibodies for 20 min. The following antibodies were purchased from BioLegend: CD3-PerCP/Cy5.5 (UCHT1), CD3-PE/Cy7 (UCHT1), CD27-FITC (O323), CD38-PE/Cy7 (HIT2), CD19-APC/Cy7 (HIB19), CD45RA-APC/Cy7 (HI100), CD16-PerCP/Cy5.5 (3G8), CD56-APC/Cy7 (HCD56), CCR7-PerCP/Cy5.5 (G043H7), CD14-FITC (M5E2), and CD25-BV421 (BC96). The following antibodies were purchased from BD: CD24-PE (ML5), IgD-BV421 (IA6-2), CXCR5-AF488 (RF8B2), CCR6-PE (11A9), CXCR3-BV421 (1C6/CXCR3), CD4-V500 (RPA-T4) and CD19-V500 (HIB19). CD25-PE/Cy7 (BC96), HLADR-PE (L243), and CD127-PE/Cy7 (eBioRDR5) were purchased from eBioscience, and LAG3-PE (FAB2319P) was purchased from R&D. We classified CD4+ T cells, B cells, natural killer (NK) cells and monocytes based on the Human Immunology Project classification (20). Cell subset definitions of surface markers are shown in Table 1, and the gating strategy is shown in Figure 1. Flow cytometric analyses were performed by 8-color MoFlo XDP (Beckman Coulter). Flow cytometric data were analyzed using FlowJo software (Tree Star).
Figure 1. Gating strategy of flow cytometric analysis. (A) Gating strategy for naïve CD4+ T cells, CD25+ regulatory T cells (CD25+ Tregs), activated CD25+ regulatory T cells (activated CD25+ Tregs), CD25−LAG3 T cells, and CD25+LAG3+ T cells. (B) Gating strategy for follicular helper T cells (Tfh), helper T cells (Th), Th1, Th17, Th1/17, and non Th1/17. (C) Gating strategy for B cell subsets (naïve B cells, switched memory B cells (Sw MB), unswitched memory B cells (UnSw MB), plasmablasts and transitional B cells). (D) Gating strategy for NK cells. (E) Gating strategy for monocyte subsets (classical monocytes, intermediate monocytes and non-classical monocytes).
RNA Isolation, cDNA Synthesis, and Quantitative Real-Time PCR
Naïve CD4+ T cells, activated CD25+ Tregs, CD25−LAG3+ T cells, CD25+LAG3+ T cells were sorted and stimulated for 72 h on flat-bottom 96-well microplates pre-coated with anti-CD3ε monoclonal antibody (mAb) (10 μg/mL) and anti-human CD28 mAb (5 μg/mL). The culture medium was RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 100 U/mL penicillin, 100 mg/mL streptomycin, 50 mM 2-ME (all purchased from Life Technologies) and recombinant human IL-2 (100 IU/mL, R&D). After staining with 7-AAD Viability Staining Solution (BioLegend), 7-AAD-negative cells were sorted.
For FOXP3 expression analysis, sorted Naïve CD4+ T cells, activated CD25+ Tregs, CD25−LAG3+ T cells, CD25+LAG3+ T cells were analyzed. For RORC expression analysis, sorted Naïve CD4+ T cells, activated CD25+ Tregs, CD25−LAG3+ T cells, CD25+LAG3+ T cells stimulated for 72 h with anti-CD3ε monoclonal antibody (mAb) (10 μg/mL) and anti-human CD28 mAb (5 μg/mL) were analyzed. Total RNA was extracted using the RNeasy Micro Kit (QIAGEN) and then reverse-transcribed to cDNA with random primers (Invitrogen) and Superscript III (Invitrogen), according to the manufacturer's protocol. To determine the cellular expression of each gene, quantitative real-time PCR analysis was performed using CFX connect (Bio-Rad). The PCR mixture consisted of 10 μL SYBR Green Master Mix (QIAGEN), 15 pM forward and reverse primers, and the cDNA samples in a total volume of 20 μL. We calculated the quantitative PCR data with the D threshold cycle method, and relative RNA abundance was determined based on control GAPDH abundance. The real-time PCR primer pairs were as follows: human FOXP3 sense, 5′-GAAACAGCACATTCCCAGAGTTC-3′ and antisense, 5′-ATGGCCCAGCGGATGAG-3′; human RORC sense, 5′-CAGTCATGAGAACACAAATTGAAGTG-3′ and antisense, 5′-CAGGTGATAACCCCGTAGTGGAT-3′; human GAPDH sense, 5′-GAAGGTGAAGGTCGGAGTC-3′ and antisense, 5′-GAAGATGGTGATGGGATTTC-3′.
Intracellular Staining Analysis
Naïve CD4+ T cells, activated CD25+ Tregs, CD25−LAG3+ T cells, CD25+LAG3+ T cells, and CD4+CD25−LAG3−CD45RA− T cells (Memory CD4+ T cells) were sorted and stimulated for 72 h with anti-CD3ε mAb (10 μg/mL) and anti-human CD28 mAb (5 μg/mL) in the presence of recombinant human IL-2 (100 IU/mL). Twelve hours prior to cytokine production analysis, phorbol 12-myristate 13-acetate (PMA) (25 ng/mL), ionomycin (1 μg/mL) and protein transport inhibitor GolgiStop (BD) were added. After staining with 7-AAD, intracellular staining was performed using Cytofix/Cytoperm Fixation/Permeabilization Kit (BD) following the manufacturer's instructions. For cytokine production analysis, IFN-γ-FITC (4S.B3, eBioscience), IL-4-APC (8D4-8, BioLegend), IL-17A-APC (eBio64DEC17, eBioscience) or IL-10-Alexa Fluor 660 (JES3-9D7, eBioscience) antibodies were used. For staining Foxp3, Foxp3 Staining Buffer Set (eBioscience) and Foxp3-FITC (PCH101, eBioscience) antibody were used.
T Cell Suppression Assay
CD4+ naïve T cells were purified by magnetic cell separation (MACS) using the Naïve CD4+ T Cell Isolation Kit II (Miltenyi Biotech), after which cells were labeled with 2 mM CFSE (Dojindo). CD3-negative cells were sorted by flow cytometry and used as antigen presenting cells (APCs) after 30 Gy irradiation. CFSE-labeled CD4+ naïve T cells (5 × 104) and 1 × 105 APCs were co-cultured with 5 x 104 CD4+ naïve T cells, activated CD25+ Tregs or CD25+LAG3+ T cells on U-bottom 96-well plates that had been coated with anti-CD3ε mAb (10 μg/mL) and anti-human CD28 mAb (5 μg/mL) overnight. The decrease in CFSE intensity in viable cells was assessed 72 h later.
Data are presented as means ± standard deviation. To evaluate statistical differences between two unpaired groups, Mann-Whitney U test was used. To evaluate statistical differences between paired samples, paired Student's t-test was used. To compare three or more groups, Kruskal-Wallis test followed by Dunn's multiple comparison test or one-way ANOVA followed by Tukey's multiple comparisons test was used. To assess correlations, Spearman's rank correlation coefficient was used. To assess categorical data, Fisher's exact test was used. P-values <0.05 were considered statistically significant. Calculations were conducted using GraphPad Prism version 5.03 (GraphPad Software Inc.) and R version 3.2.3.
Clinical data describing 26 SLE patients, 30 RA patients and 30 HC donors are summarized in Table 2. The ages of SLE and HC were not significantly different, although the ages were significantly higher in RA. There was no significant difference in the sex ratio among SLE, RA, and HC. The WBC count was elevated in RA compared with HC, and the lymphocyte count was significantly lower in SLE compared with HC. In SLE, the average of total complement activity (CH50) was within normal range (31.8–48.7 U/mL), while anti-dsDNA antibody titer was higher than the cut off value (10 IU/mL). The average SLEDAI score was 9.6, and 5 patients (19.2%) had lupus nephritis, and 8 patients (30.8%) had neuropsychiatric SLE (NPSLE).
In SLE, Immature Cell Frequencies Decreased and Activated Cells Increased in Both T and B Cell Populations
We compared subset frequencies of CD4+ T cells, B cells, monocytes and NK cells among HC, RA and SLE (Figures 2A–D). Compared to HC and RA, the frequency of naïve CD4+ T cells was significantly lower, and the frequencies of activated CD25+ Tregs, CD25+LAG3+ T cells, Th1, Th2 and Th17 were significantly higher in SLE (Figure 2A). With regard to B cell subsets, the frequencies of naïve B cells, unswitched memory B cells (UnSw MB) and transitional B cells (Trans B) were significantly lower in SLE compared to both HC and RA (Figure 2B). In contrast, the frequencies of switched memory B cells (Sw MB) and plasmablasts (PB) were significantly higher in SLE compared to HC and RA (Figure 2B). In both T and B cells, we commonly observed that naïve or inactive cells were decreased whereas activated and mature cells were increased in SLE. Representative flow cytometric findings shown in Figure 2E indicated that the frequency of CD25+LAG3+ T cells was higher in SLE compared with both HC and RA.
Figure 2. Frequencies of cell subsets in PBMC of HC, RA, and SLE. With regard to SLE samples taken multiple times from the same patient during treatment, the first sample taken before treatment was chosen. (A) Frequencies of CD4+ T cell subsets in CD4+ T cells. (B) Frequencies of B cell subsets in CD19+ B cells. (C) Frequencies of monocyte subsets in monocytes. (D) Frequencies of NK cells in lymphocytes. Small horizontal lines indicates the mean. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. Kruskal-Wallis test followed by Dunn's multiple comparison test. (E) Representative flow cytometric findings showing CD25 and LAG3 expression in CD4+ gated PBMC of HC, RA, and SLE.
The Frequency of CD25+LAG3+ T Cells Was High in Active SLE and Positively Correlated With SLEDAI
In order to identify the subset that was best correlated with the clinical state of SLE patients, we calculated Spearman's rank correlation coefficient between frequencies of cell subsets and SLE clinical traits including SLEDAI, WBC count, lymphocyte count, total complement activity, anti-dsDNA antibody titer, history of lupus nephritis (LN) and history of neuropsychiatric SLE (NPSLE) (Figure 3A). Analyses were performed on all cases, including samples taken multiple times during treatment. The frequencies of CD25+LAG3+ T cells and CD14dimCD16+ monocytes (non-classical monocytes) significantly correlated with SLEDAI scores. A scatter plot of the frequencies of CD25+LAG3+ cells vs. SLEDAI scores showed a significantly positive correlation (Spearman's rho = 0.396, P = 0.022) (Figure 3B). We divided SLE patients into two groups according to the SLEDAI 10, and compared frequencies of cell subsets (Figures 3C–F). In active SLE, the frequencies of CD25+LAG3+T cells and CD14+CD16− cells (classical monocytes) were significantly higher and the frequency of non-classical monocytes was significantly lower.
Figure 3. Frequencies of CD25+LAG3+ T cells correlated with high disease activity of SLE. (A) Correlogram showing the correlation between frequencies of cell subsets in SLE and clinical traits including SLEDAI, white blood cell count (WBC), lymphocyte count (Lym), total complement activity (CH50), anti-dsDNA antibody titer (dsDNA), history of lupus nephritis (LN), and history of neuropsychiatric SLE (NPSLE). Analyses were performed on all cases including samples taken multiple times during treatment [n = 33 (activated CD25+ Treg, CD25+ Treg, CD25−LAG3+, and CD25+LAG3+), n = 32 (other subsets)]. Numbers in the matrix show Spearman's rho. *P < 0.05; **P <0.01; ***P <0.001. Spearman's rank correlation coefficient. (B) Scatter plot of frequencies of CD25+LAG3+ cells vs. SLEDAI score (n = 33). (C–F) Frequencies of PBMC subsets in SLE were compared between patients with SLEDAI less than 10 (n = 17) and patients with SLEDAI >10 [n = 16 (activated CD25+ Treg, CD25+ Treg, CD25−LAG3+, and CD25+LAG3+), n = 15 (remaining subsets)]. *P < 0.05; Mann-Whitney U test. (C) CD4+ T cell subsets, (D) B cell subsets, (E) Monocyte subset, and (F) NK cell.
CD25+LAG3+T Cells Decreased After Treatment
Four SLE patients were sequentially analyzed before and after treatment, and the effect of treatment on the frequencies of naïve CD4+ T cells and regulatory T cell subsets was observed (Figure 4A). CD25+LAG3+T cells had a significant tendency to decrease after treatment. One SLE patient with NPSLE at the onset (SLEDAI = 22) resolved 2 months after treatment (SLEDAI = 8), and relapsed with new skin rash 10 months later (SLEDAI = 12). The frequency of CD25+LAG3+T cells decreased after treatment, but increased again coincident with SLE activity (Figure 4B).
Figure 4. Frequencies of CD25+LAG3+ T cells decrease after SLE treatment. (A) Four SLE patients were sequentially analyzed before and after treatment. Frequencies of naïve CD4+ T cells and regulatory T cell subsets were compared between before (Pre) and after treatment (Post). *P < 0.05; paired-T test. (B) Sequential flow cytometric findings showing CD25 and LAG3 expression in CD4+ gated PBMC of a patient with SLE. Analysis was performed at the onset with NPSLE (SLEDAI = 22), the resolution 2 months after treatment (SLEDAI = 8) and the relapse with new skin rash 10 months later (SLEDAI = 12).
CD25+LAG3+ T Cells Have Features of Both CD25+ Treg and Th17
In order to clarify the character of cell subsets, naïve CD4+ T cells, CD25−LAG3+ T cells, CD25+LAG3+ T cells, activated CD25+ Tregs and CD4+CD25−LAG3−CD45RA− T cells (Memory CD4+ T cells) were sorted from the PBMC donated by HC. Intracellular staining was performed to evaluate the production of cytokines and the expression of FOXP3. Representative flow cytometric findings showed that CD25−LAG3+ T cells produced high amounts of both IFN-γ and IL-10, in agreement with an earlier reports (23, 24). CD25+LAG3+ T cells expressed high amounts of both IL-17A and FOXP3 (Figure 5A). Intracellular staining of three HC individuals showed that CD25−LAG3+ T cells and memory CD4+ T cells expressed high amounts of IFN-γ. Activated CD25+ Tregs expressed the highest amount of FOXP3, and CD25+LAG3+ T cells expressed the secondary highest amount of FOXP3. CD25+LAG3+ T cells expressed the higher amount of IL-17A compared with naïve, memory and CD25−LAG3+ T cells (Figure 5B). With regard to mRNA expression, activated CD25+ Treg expressed the highest amount of FOXP3. CD25+LAG3+T cells expressed a fairly small amount of FOXP3, and high amounts of RORC (Figure 5C).
Figure 5. Cytokine and mRNA expression analysis. Naïve CD4+ T cells (Naïve), CD25−LAG3+ T cells (CD25−LAG3+), CD25+LAG3+ T cells (CD25+LAG3+), activated CD25+ Tregs and CD4+CD25−LAG3−CD45RA− T cells (Memory) donated by HC were analyzed. (A) Representative findings of intracellular staining. CD4+ T cell subsets were separated by sorting and stimulated for 72 h with anti-CD3ε mAb (10 μg/mL) and anti-human CD28 mAb (5 μg/mL) in the presence of recombinant human IL-2 (100 IU/mL). (B) Summary of intracellular staining of CD4+ T cell subsets taken from three HC individuals. *P < 0.05; **P < 0.01; ***P < 0.001. One-way ANOVA followed by Tukey's multiple comparisons test. (C) Relative mRNA expression of FOXP3 compared to GAPDH in sorted CD4+ T cell subsets (n = 3) without stimulation. Relative mRNA expression of RORC compared to GAPDH in sorted CD4+ T cell subsets (n = 3) stimulated for 72 h with anti-CD3ε mAb (10 μg/mL) and anti-human CD28 mAb (5 μg/mL) in the presence of recombinant human IL-2 (100 IU/mL). Cell subsets were **P < 0.01; ***P < 0.001; ****P < 0.0001. One-way ANOVA followed by Tukey's multiple comparisons test.
CD25+LAG3+ T Cells Did Not Show Suppressive Activity
Activated CD25+ Treg and CD25+LAG3+ T cells were sorted, and we investigated their suppressive ability by co-culturing them with CFSE-labeled naïve CD4+ T cells and antigen presenting cells. While activated CD25+ Treg showed the expected suppressive activity, CD25+LAG3+ T cells did not show the evident suppressive activity as activated CD25+ Treg demonstrated (Figure 6).
Figure 6. T cell suppression assay. CFSE labeled CD4+ naïve T cells were co-cultured with irradiated APCs and CD4+ T cell subsets (naïve CD4+ T cells, CD25+LAG3+ T cells and activated CD25+ Tregs) in the presence of anti-CD3ε mAb (10 μg/mL) and anti-human CD28 mAb (5 μg/mL). CFSE dilution of viable cells was assessed 72 h later. Flow cytometric data show results from one representative experiment out of three independent experiments. Percentages of proliferating cells are presented.
We compared the frequencies of various immune cell subsets in PBMC collected from HC, RA and SLE groups. Our observations in SLE were consistent with previous reports showing decreases of naïve CD4+ T cells (5, 6) and naïve B cells (10) and an increase of memory B cells and plasmablasts (11, 19).
About markers of Treg, CD25 and FOXP3 can be expressed by activated non-Tregs (27) without a stable regulatory phenotype (28). CD25 is a poor marker of Tregs in SLE because of the high number of non-Treg cells in the CD25high population, therefore several markers had been proposed to evaluate Treg in SLE. GITR, which is expressed at high levels in activated T cells and Treg (29), was used to identify CD4+CD25low/−GITR+ cells that expand in SLE patients with inactive disease that exert a high inhibitory activity (30). Moreover, Helios, an Ikaros family member, was used to identify FOXP3+Helios+ cells as activated CD25+ Tregs that were increased in SLE (18). We defined CD4+CD25+CD127lowCD45RA− T cells as activated CD25+ Treg since this definition is widely accepted to enrich activated CD25+ Treg in human samples (31). We confirmed that the frequency of activated CD25+ Treg was significantly higher in SLE as shown earlier (32, 33). On the other hand, these subsets were not significantly correlated with SLEDAI.
We found that CD25+LAG3+ T cells was significantly increased in SLE. The frequency of CD25+LAG3+ T cells was significantly correlated with SLEDAI and decreased after treatment. These results implied that CD25+LAG3+ T cells might be involved in the pathophysiology of SLE. CD25+LAG3+ T cells expressed FOXP3, albeit less than activated CD25+ Tregs did, but they did not have apparent regulatory activity. We suggest that the expression of FOXP3 in CD25+LAG3+ T cells resulted from T cell activation in SLE (34).
On the other hand, CD25+LAG3+ T cells expressed a high amount of RORC and IL-17 as well as FOXP3, a characteristic of IL-17-producing FOXP3+ T cells (35). Apart from the reciprocal relationship of Th17 and Treg cells, the plasticity between Th17 and Foxp3+CD25+ Treg has been observed (36). The in vitro conversion from Foxp3+CD25+Treg to Th17-like Tregs is dependent on IL-1β and on epigenetic modification (37). IL-17-secreting Tregs express RORγt (36) and were suppressive in vitro (38), but they rapidly lost their suppressive capacity upon strong activation in the presence of IL-1β and IL-6 (39). There also seems to exist mechanisms that allow the rapid shutdown of suppression and the induction of pro-inflammatory responses in Treg cells. Tumor infiltrating Tregs were rapidly converted into Th17 cells, down-regulated FOXP3 expression and lost their suppressive capacity (40).
About the issue of the switch between Th17 and Treg cells, it is still difficult to conclude the origin of CD25+LAG3+ T cells. There is the possibility that Th17 shifted to Treg (41). Considering the result of qPCR of unstimulated cells (Figure 5C), CD25+LAG3+ T cells might be a transient state of Th17 cells switching to the Treg phenotype. However, there are more reports that Treg shifted to IL-17-producing FOXP3+ T cells (35–37). Immunological milieu in SLE that both innate immunity and acquired immunity are activated might induce shift from Foxp3+CD25+ Treg to IL-17-producing FOXP3+ T cells. More confirmations should be performed.
There are several reports regarding the relevance of IL-17-producing FOXP3+ T cells in autoimmune diseases. IL-17-producing FOXP3+ T cells were highly enriched within the inflammatory environment of childhood arthritis, suggesting a role in the disease (42). IL-17-producing FOXP3+ T cells were recently associated with psoriasis (43) and systemic sclerosis (44). Recently, it was reported that IL-17-producing FOXP3+ T cells were associated with pathogenicity in a lupus model mouse in a RORγt-dependent manner (45). These cells potently suppress anti-inflammatory Th2 immunity in a RORγt-dependent manner, and they advocates these cells as novel players in SLE.
The reason why the expression of LAG3 in CD4+CD25+ T cells could be a marker of IL-17-producing FOXP3+ T cells remains to be solved. It was recently reported that environmental stimuli-induced intraepithelial lymphocytes (IELs) in the gut had a Th17-like profile and markedly upregulate LAG3 expression (46). They proliferated in response to gut-derived antigens and potentially prevent autoimmunity. Moreover, CCR9+ memory T cells in CSF of patients with secondary progressive multiple sclerosis expressed high level of LAG3 and RORγt. They produced high amount of IL-17A and presented a loss of regulatory function (47). FOXP3+RORγt+ Tregs were increased in PBMC from patients with pancreatic ductal adenocarcinoma, and they produced IL-17A and expressed high level of LAG3. They suppressed T cell immune responses, but enhanced inflammation (48). Thus, there are several reports of LAG3 expression on Th17 type cells. LAG3 is a surface marker that can be expressed by activation (49), therefore immunological milieu in SLE that induce shift to IL-17-producing FOXP3+ T cells might induce the expression of LAG3. Moreover, Egr2, which is a key transcription factor of CD25−LAG3+ T cells (50), is reported to be a positive regulator for Th17 cell development in a network analysis (51). Egr2 might be associated with the expression of LAG3 in IL-17-producing FOXP3+ T cells in SLE. However, the relationship between LAG3 and RORC or IL-17 production remains to be elucidated.
There are several limitations in our analysis. First, the number of patients (26 SLE patients, 30 RA patients and 30 healthy controls) were relatively small. Second, because the number of patients performing cell frequencies analysis of before and after treatment was limited, further confirmation is necessary regarding decrease of frequencies of CD25+LAG3+ T cells after treatment. Third, there is a possibility that anti-human LAG3 antibody might affect the result of T cell suppression assay. Forth, since the number of IL-17+ cells in CD4+CD25+LAG3+ T cells is not so high, there might be another mechanism for CD4+CD25+LAG3+ T cells not to show evident suppressive activity.
In summary, CD25+LAG3+ T cells are low in frequency in HC and RA, but significantly greater in SLE. The frequency of CD25+LAG3+ T cells was significantly positively correlated with the SLEDAI score and was reduced by treatment. CD25+LAG3+ T cells expressed both FOXP3, RORC and IL-17A, suggesting that they were IL-17-producing FOXP3+ T cells.
The datasets generated for this study are available on request to the corresponding author.
All clinical investigations conformed to the Declaration of Helsinki principles and were approved by the ethics committee of the University of Tokyo (No. 10154 and G3582). Peripheral blood and clinical data were collected after getting written informed consent in accordance with our ethical review board.
RK and SS equally contributed to this manuscript. RK, SS, YT, HT, SN, TO, KY, and KF conceived, designed and analyzed the experiments, and contributed to writing the manuscript. RK and SS carried out all experiments. KS, NH, YN, KK, ST, and HK helped with obtaining human samples and clinical data.
This work was supported by the Ministry of Health, Labor and Welfare, Ministry of Education, Culture, Sports, Science and Technology KAKENHI Grant-in-Aid for Scientific Research (S) (23229007), Grant-in-Aid for challenging Exploratory Research (25670459) and Grant-in-Aid for Young Scientists (B) (15K19566) from the Japan Society for the Promotion of Science.
Conflict of Interest Statement
SS received financial support or fees from AbbVie, Eisai, Chugai, UCB, BMS, Takeda, AstraZeneca, Pfizer, MitsubishiTanabe, Novartis Pharma, and Asahi Kasei. TO received financial support or fees from Chugai, Novartis Pharma. KY received financial support or fees from AbbVie, Astellas, BMS, Daiichi-Sankyo, MitsubishiTanabe, Pfizer, Sanofi, Santen, Takeda, Teijin, Boehringer Ingelheim, Chugai, Eisai, Ono, Taisho Toyama, UCB, ImmunoFuture, Asahi Kasei, and Janssen. KF received financial support or fees from Astellas, BMS, Daiichi-Sankyo, MitsubishiTanabe, Pfizer, Santen, Takeda, Chugai, Eisai, Taisho Toyama, UCB, and Janssen.
The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
We thank the patients and healthy volunteers who participated in this research. We thank H. Shoda, H. Harada, M. Shibuya, Y. Iwasaki, K. Michishita, T. Eri, Y. Seri, and M. Ohshima for their help in collecting patients' data.
2. Dieker J, Tel J, Pieterse E, Thielen A, Rother N, Bakker M, et al. Circulating apoptotic microparticles in systemic lupus erythematosus patients drive the activation of dendritic cell subsets and prime neutrophils for NETosis. Arthritis Rheumatol. (2016) 68:462–72. doi: 10.1002/art.39417
5. Gordon C, Matthews N, Schlesinger BC, Akbar AN, Bacon PA, Emery P, et al. Active systemic lupus erythematosus is associated with the recruitment of naive/resting T cells. Br J Rheumatol. (1996) 35:226–30.
6. Watanabe T, Suzuki J, Mitsuo A, Nakano S, Tamayama Y, Katagiri A, et al. Striking alteration of some populations of T/B cells in systemic lupus erythematosus: relationship to expression of CD62L or some chemokine receptors. Lupus. (2008) 17:26–33. doi: 10.1177/0961203307085246
7. Tucci M, Lombardi L, Richards HB, Dammacco F, Silvestris F. Overexpression of interleukin-12 and T helper 1 predominance in lupus nephritis. Clin Exp Immunol. (2008) 154:247–54. doi: 10.1111/j.1365-2249.2008.03758.x
9. Simpson N, Gatenby PA, Wilson A, Malik S, Fulcher DA, Tangye SG, et al. Expansion of circulating T cells resembling follicular helper T cells is a fixed phenotype that identifies a subset of severe systemic lupus erythematosus. Arthritis Rheum. (2010) 62:234–44. doi: 10.1002/art.25032
10. Odendahl M, Jacobi A, Hansen A, Feist E, Hiepe F, Burmester GR, et al. Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J Immunol. (2000) 165:5970–9. doi: 10.4049/jimmunol.165.10.5970
11. Arce E, Jackson DG, Gill MA, Bennett LB, Banchereau J, Pascual V. Increased frequency of pre-germinal center B cells and plasma cell precursors in the blood of children with systemic lupus erythematosus. J Immunol. (2001) 167:2361–9. doi: 10.4049/jimmunol.167.4.2361
12. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains. (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. (1995) 155:1151–64.
16. Yang J, Yang X, Zou H, Chu Y, Li M. Recovery of the immune balance between Th17 and regulatory T cells as a treatment for systemic lupus erythematosus. Rheumatology. (2011) 50:1366–72. doi: 10.1093/rheumatology/ker116
17. Golding A, Hasni S, Illei G, Shevach EM. The percentage of FoxP3+Helios+ Treg cells correlates positively with disease activity in systemic lupus erythematosus. Arthritis Rheum. (2013) 65:2898–906. doi: 10.1002/art.38119
18. Alexander T, Sattler A, Templin L, Kohler S, Gross C, Meisel A, et al. Foxp3+ Helios+ regulatory T cells are expanded in active systemic lupus erythematosus. Ann Rheum Dis. (2013) 72:1549–58. doi: 10.1136/annrheumdis-2012-202216
19. Jacobi AM, Odendahl M, Reiter K, Bruns A, Burmester GR, Radbruch A, et al. Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum. (2003) 48:1332–42. doi: 10.1002/art.10949
22. Gagliani N, Magnani CF, Huber S, Gianolini ME, Pala M, Licona-Limon P, et al. Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells. Nat Med. (2013) 19:739–46. doi: 10.1038/nm.3179
23. Okamura T, Sumitomo S, Morita K, Iwasaki Y, Inoue M, Nakachi S, et al. TGF-beta3-expressing CD4+CD25(-)LAG3+ regulatory T cells control humoral immune responses. Nat Commun. (2015) 6:6329. doi: 10.1038/ncomms7329
24. Nakachi S, Sumitomo S, Tsuchida Y, Tsuchiya H, Kono M, Kato R, et al. Interleukin-10-producing LAG3+ regulatory T cells are associated with disease activity and abatacept treatment in rheumatoid arthritis. Arthritis Res Ther. (2017) 19:97. doi: 10.1186/s13075-017-1309-x
25. Sumitomo S, Nakachi S, Okamura T, Tsuchida Y, Kato R, Shoda H, et al. Identification of tonsillar CD4+CD25-LAG3+ T cells as naturally occurring IL-10-producing regulatory T cells in human lymphoid tissue. J Autoimmun. (2017) 76:75–84. doi: 10.1016/j.jaut.2016.09.005
26. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. (1992) 35:630–40. doi: 10.1002/art.1780350606
27. Gavin MA, Torgerson TR, Houston E, DeRoos P, Ho WY, Stray-Pedersen A, et al. Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development. Proc Natl Acad Sci USA. (2006) 103:6659–64. doi: 10.1073/pnas.0509484103
28. Tran DQ, Ramsey H, Shevach EM. Induction of FOXP3 expression in naive human CD4+FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-beta dependent but does not confer a regulatory phenotype. Blood. (2007) 110:2983–90. doi: 10.1182/blood-2007-06-094656
29. Levings MK, Sangregorio R, Sartirana C, Moschin AL, Battaglia M, Orban PC, et al. Human CD25+CD4+ T suppressor cell clones produce transforming growth factor beta, but not interleukin 10, and are distinct from type 1 T regulatory cells. J Exp Med. (2002) 196:1335–46. doi: 10.1084/jem.20021139
30. Nocentini G, Alunno A, Petrillo MG, Bistoni O, Bartoloni E, Caterbi S, et al. Expansion of regulatory GITR+CD25 low/-CD4+ T cells in systemic lupus erythematosus patients. Arthritis Res Ther. (2014) 16:444. doi: 10.1186/s13075-014-0444-x
31. Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med. (2006) 203:1701–11. doi: 10.1084/jem.20060772
32. Lin SC, Chen KH, Lin CH, Kuo CC, Ling QD, Chan CH. The quantitative analysis of peripheral blood FOXP3-expressing T cells in systemic lupus erythematosus and rheumatoid arthritis patients. Eur J Clin Invest. (2007) 37:987–96. doi: 10.1111/j.1365-2362.2007.01882.x
33. Yan B, Ye S, Chen G, Kuang M, Shen N, Chen S. Dysfunctional CD4+,CD25+ regulatory T cells in untreated active systemic lupus erythematosus secondary to interferon-alpha-producing antigen-presenting cells. Arthritis Rheum. (2008) 58:801–12. doi: 10.1002/art.23268
34. Bonelli M, von Dalwigk K, Savitskaya A, Smolen JS, Scheinecker C. Foxp3 expression in CD4+ T cells of patients with systemic lupus erythematosus: a comparative phenotypic analysis. Ann Rheum Dis. (2008) 67:664–71. doi: 10.1136/ard.2007.074690
35. Ayyoub M, Deknuydt F, Raimbaud I, Dousset C, Leveque L, Bioley G, et al. Human memory FOXP3+ Tregs secrete IL-17 ex vivo and constitutively express the T(H)17 lineage-specific transcription factor RORgamma t. Proc Natl Acad Sci USA. (2009) 106:8635–40. doi: 10.1073/pnas.0900621106
37. Koenen HJ, Smeets RL, Vink PM, van Rijssen E, Boots AM, Joosten I. Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells. Blood. (2008) 112:2340–52. doi: 10.1182/blood-2008-01-133967
38. Voo KS, Wang YH, Santori FR, Boggiano C, Wang YH, Arima K, et al. Identification of IL-17-producing FOXP3+ regulatory T cells in humans. Proc Natl Acad Sci USA. (2009) 106:4793–8. doi: 10.1073/pnas.0900408106
39. Beriou G, Costantino CM, Ashley CW, Yang L, Kuchroo VK, Baecher-Allan C, et al. IL-17-producing human peripheral regulatory T cells retain suppressive function. Blood. (2009) 113:4240–9. doi: 10.1182/blood-2008-10-183251
40. Leveque L, Deknuydt F, Bioley G, Old LJ, Matsuzaki J, Odunsi K, et al. Interleukin 2-mediated conversion of ovarian cancer-associated CD4+ regulatory T cells into proinflammatory interleukin 17-producing helper T cells. J Immunother. (2009) 32:101–8. doi: 10.1097/CJI.0b013e318195b59e
42. Pesenacker AM, Bending D, Ursu S, Wu Q, Nistala K, Wedderburn LR. CD161 defines the subset of FoxP3+ T cells capable of producing proinflammatory cytokines. Blood. (2013) 121:2647–58. doi: 10.1182/blood-2012-08-443473
43. Bovenschen HJ, van de Kerkhof PC, van Erp PE, Woestenenk R, Joosten I, Koenen HJ. Foxp3+ regulatory T cells of psoriasis patients easily differentiate into IL-17A-producing cells and are found in lesional skin. J Invest Dermatol. (2011) 131:1853–60. doi: 10.1038/jid.2011.139
44. Liu X, Gao N, Li M, Xu D, Hou Y, Wang Q, et al. Elevated levels of CD4+CD25+FoxP3+ T cells in systemic sclerosis patients contribute to the secretion of IL-17 and immunosuppression dysfunction. PLoS ONE. (2013) 8:e64531. doi: 10.1371/journal.pone.0064531
45. Kluger MA, Nosko A, Ramcke T, Goerke B, Meyer MC, Wegscheid C, et al. RORgammat expression in Tregs promotes systemic lupus erythematosus via IL-17 secretion, alteration of Treg phenotype and suppression of Th2 responses. Clin Exp Immunol. (2017) 188:63–78. doi: 10.1111/cei.12905
46. Kadowaki A, Miyake S, Saga R, Chiba A, Mochizuki H, Yamamura T. Gut environment-induced intraepithelial autoreactive CD4+ T cells suppress central nervous system autoimmunity via LAG-3. Nat Commun. (2016) 7:11639. doi: 10.1038/ncomms11639
47. Kadowaki A, Saga R, Lin Y, Sato W, Yamamura T. Gut microbiota-dependent CCR9+CD4+ T cells are altered in secondary progressive multiple sclerosis. Brain. (2019) 142:916–31. doi: 10.1093/brain/awz012
48. Chellappa S, Hugenschmidt H, Hagness M, Line PD, Labori KJ, Wiedswang G, et al. Regulatory T cells that co-express RORgammat and FOXP3 are pro-inflammatory and immunosuppressive and expand in human pancreatic cancer. Oncoimmunology. (2016) 5:e1102828. doi: 10.1080/2162402X.2015.1102828
49. Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT: Co-inhibitory receptors with specialized functions in immune regulation. Immunity. (2016) 44:989–1004. doi: 10.1016/j.immuni.2016.05.001
50. Okamura T, Fujio K, Shibuya M, Sumitomo S, Shoda H, Sakaguchi S, et al. CD4+CD25-LAG3+ regulatory T cells controlled by the transcription factor Egr-2. Proc Natl Acad Sci USA. (2009) 106:13974–9. doi: 10.1073/pnas.0906872106
Keywords: systematic lupus erythematosus, LAG3, regulatory T cells, Th17, SLEDAI
Citation: Kato R, Sumitomo S, Tsuchida Y, Tsuchiya H, Nakachi S, Sakurai K, Hanata N, Nagafuchi Y, Kubo K, Tateishi S, Kanda H, Okamura T, Yamamoto K and Fujio K (2019) CD4+CD25+LAG3+ T Cells With a Feature of Th17 Cells Associated With Systemic Lupus Erythematosus Disease Activity. Front. Immunol. 10:1619. doi: 10.3389/fimmu.2019.01619
Received: 23 March 2019; Accepted: 28 June 2019;
Published: 12 July 2019.
Edited by:Laurence Morel, University of Florida, United States
Reviewed by:Hai-Feng Pan, Anhui Medical University, China
Giuseppe Nocentini, University of Perugia, Italy
Carlo Riccardi, University of Perugia, Italy
Copyright © 2019 Kato, Sumitomo, Tsuchida, Tsuchiya, Nakachi, Sakurai, Hanata, Nagafuchi, Kubo, Tateishi, Kanda, Okamura, Yamamoto and Fujio. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Keishi Fujio, email@example.com
†These authors have contributed equally to this work